AgomAb Therapeutics NV (AGMB) shareholders
Close on Nov 17, 2026Market cap $148.00KP/E –Yield –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| LSP 7 Cooperatieve U.A. Joint filing with LSP 7 Management B.V. (10.60%) | 5,141,992 | 10.60% | 13D (active) | Feb 9, 2026 |
| Abigail P. Johnson Joint filing with FMR LLC (10.00%) | 4,873,680 | 10.00% | 13G (passive) | Feb 27, 2026 |
| Tomer Kariv Joint filing with Pontifax VI G.P. L.P. (6.80%), Pontifax Management 4 G.P. (2015) Ltd. (6.80%) and 1 more | 3,305,846 | 6.80% | 13G (passive) | Mar 31, 2026 |
| Sanofi | 2,783,096 | 5.71% | 13G (passive) | Mar 31, 2026 |
| Redmile Group, LLC Joint filing with Jeremy C. Green (5.60%), Redmile Biopharma Investments III, L.P. (5.60%) | 2,735,926 | 5.60% | 13G (passive) | Mar 31, 2026 |
| Bihua Chen Joint filing with Cormorant Asset Management, LP (5.01%) | 2,465,348 | 5.01% | 13G (passive) | Mar 31, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of AGMB | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| EQT Fund Management S.a r.l. | 5,141,992 | 15.05% | $66.74M | – | 7.74% |
| Nantahala Capital Management, LLC | 3,136,376 | 9.18% | $40.71M | +1,936,376 | 0.68% |
| Sanofi | 2,783,096 | 8.15% | $36.12M | – | 6.76% |
| Redmile Group, LLC | 2,733,926 | 8.00% | $35.49M | +2,577,676 | 2.38% |
| Cormorant Asset Management, LP | 2,465,348 | 7.22% | $32.00M | – | 1.64% |
| TCG Crossover Management, LLC | 2,053,233 | 6.01% | $26.65M | – | 0.64% |
| Federated Hermes, Inc. | 1,618,000 | 4.74% | $21.00M | – | 0.03% |
| Casdin Capital, LLC | 1,550,000 | 4.54% | $20.12M | – | 1.01% |
| Andera Partners | 1,538,702 | 4.50% | $19.97M | – | 9.67% |
| FMR LLC | 1,458,677 | 4.27% | $18.93M | – | 0.00% |
| abrdn plc | 846,695 | 2.48% | $10.99M | +139,039 | 0.02% |
| Perceptive Advisors LLC | 600,000 | 1.76% | $7.79M | – | 0.12% |
| Samsara BioCapital, LLC | 600,000 | 1.76% | $7.79M | – | 0.64% |
| Siren, L.L.C. | 411,250 | 1.20% | $5.34M | – | 0.11% |
| Orbimed Advisors LLC | 192,740 | 0.56% | $2.50M | New | 0.05% |
| Pfizer Inc | 75,000 | 0.22% | $1.04M | – | 0.61% |
| Alps Advisors Inc | 49,984 | 0.15% | $648.79K | New | 0.00% |
| Bellevue Group AG | 49,248 | 0.14% | $639.24K | −752 | 0.01% |
| Seven Grand Managers, LLC | 47,600 | 0.14% | $617.85K | −152,400 | 0.02% |
| Sectoral Asset Management Inc | 43,500 | 0.13% | $564.63K | – | 0.39% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 34 | 28M | 80.6% | 9 / 4 | 6 / 7 | 5M | 1M |
| Q1 2026 | 32 | 23M | 68.4% | 32 / 0 | 0 / 0 | 23M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of AGMB | Value | % of fund | As of |
|---|---|---|---|---|---|
| Federated Hermes Kaufmann Fund | 981,184 | 2.87% | $12.63M | 0.26% | Jul 31, 2026 |
| Federated Hermes Kaufmann Small Cap Fund | 615,708 | 1.80% | $7.92M | 0.28% | Jul 31, 2026 |
| Fidelity Growth Company Fund | 507,877 | 1.49% | $5.71M | 0.01% | May 31, 2026 |
| Fidelity Growth Company K6 Fund | 141,356 | 0.41% | $1.59M | 0.01% | May 31, 2026 |
| Fidelity Series Growth Company Fund | 129,200 | 0.38% | $1.45M | 0.01% | May 31, 2026 |
| Federated Hermes Kaufmann Fund II | 21,108 | 0.06% | $273.98K | 0.24% | Jun 30, 2026 |
| Blackstone Alternative Multi-Strategy Fund | 17,665 | 0.05% | $229.29K | 0.01% | Jun 30, 2026 |
| Select Pharmaceuticals Portfolio | 9,100 | 0.03% | $102.38K | 0.01% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 8,746 | 0.03% | $98.39K | 0.00% | May 31, 2026 |
| Steward Values Enhanced International Fund | 4,109 | 0.01% | $52.88K | 0.02% | Jul 31, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Tim Jasper Knotnerus | Chief Executive Officer, Director | 56,217 | 0.16% | Oct 7, 2026 |
| Pierre Thadee Victor Kemula | Chief Financial Officer | 10,000 | 0.03% | Oct 7, 2026 |
| der Horst Paul Henryk van | Chief Business Officer | – | – | Mar 18, 2026 |
| Ellen Lefever | General Counsel | – | – | Mar 18, 2026 |
| Andrea Saez Borderias | Chief Development Officer | – | – | Mar 18, 2026 |
| Philippe Constantin Wiesel | Chief Medical Officer | – | – | Mar 18, 2026 |
| David R. Epstein | Director | 54,980 | 0.16% | Nov 16, 2026 |
| Marino Garcia | Director | – | – | Sep 15, 2026 |
| Naimish Patel | Director | – | – | Sep 15, 2026 |
| Ohad Hammer | Director | – | – | Mar 18, 2026 |
| Colin Michael Bond | Director | – | – | Mar 18, 2026 |
| Weegen Felice Isabel Verduyn-van | Director | – | – | Mar 18, 2026 |
| Angelika Martha Jahreis | Director | – | – | Mar 18, 2026 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| David R. Epstein Director | Nov 13, 2026 | Buy | +4,960 | $6.02 | $29.86K | 54,980 |
| David R. Epstein Director | Nov 13, 2026 | Buy | +5,000 | $5.75 | $28.75K | 50,020 |
| David R. Epstein Director | Nov 13, 2026 | Buy | +20 | $6.00 | $120 | 45,020 |
| David R. Epstein Director | Nov 13, 2026 | Buy | +5,000 | $5.99 | $29.95K | 45,000 |
| David R. Epstein Director | Nov 5, 2026 | Buy | +5,000 | $6.98 | $34.90K | 40,000 |
| David R. Epstein Director | Nov 5, 2026 | Buy | +5,000 | $6.91 | $34.55K | 35,000 |
| David R. Epstein Director | Nov 5, 2026 | Buy | +5,000 | $6.81 | $34.05K | 30,000 |
| David R. Epstein Director | Oct 21, 2026 | Buy | +5,000 | $8.90 | $44.50K | 25,000 |
| David R. Epstein Director | Oct 21, 2026 | Buy | +5,000 | $8.86 | $44.30K | 20,000 |
| David R. Epstein Director | Oct 8, 2026 | Buy | +5,000 | $8.90 | $44.50K | 15,000 |
| Tim Jasper Knotnerus Chief Executive Officer, Director | Oct 6, 2026 | Buy | +5,000 | $8.70 | $43.50K | 21,823 |
| Pierre Thadee Victor Kemula Chief Financial Officer | Oct 6, 2026 | Buy | +2,000 | $8.54 | $17.08K | 10,000 |
| Pierre Thadee Victor Kemula Chief Financial Officer | Oct 6, 2026 | Buy | +5,000 | $8.57 | $42.85K | 8,000 |
| Pierre Thadee Victor Kemula Chief Financial Officer | Oct 6, 2026 | Buy | +3,000 | $8.67 | $26.01K | 3,000 |
| David R. Epstein Director | Oct 6, 2026 | Buy | +5,000 | $8.70 | $43.50K | 10,000 |
| Tim Jasper Knotnerus Chief Executive Officer, Director | Oct 5, 2026 | Buy | +6,000 | $8.48 | $50.88K | 16,823 |
| David R. Epstein Director | Oct 5, 2026 | Buy | +5,000 | $8.57 | $42.85K | 5,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 9 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of AgomAb Therapeutics's stock actually held short. Settlement fails (shares not delivered on time) peaked at 23,440 shares on Aug 21, 2026 over the last 90 days.
See a number that looks wrong?